IWC
NBIX icon

Integrated Wealth Concepts’s Neurocrine Biosciences NBIX Stock Holding History

Integrated Wealth Concepts’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
8,041
-5,703
-41% -$846K 0.01% 1036
2026
Q1 		$1.81M Buy
13,744
+7,085
+106% +$940K 0.01% 796
2025
Q4 		$944K Sell
6,659
-1,490
-18% -$216K 0.01% 796
2025
Q3 		$1.14M Buy
8,149
+3,796
+87% +$514K 0.01% 914
2025
Q2 		$547K Sell
4,353
-2,880
-40% -$330K 0.01% 1221
2025
Q1 		$800K Buy
7,233
+4,526
+167% +$573K 0.01% 923
2024
Q4 		$370K Buy
2,707
+757
+39% +$93.6K ﹤0.01% 1261
2024
Q3 		$225K Sell
1,950
-143
-7% -$19.6K ﹤0.01% 1506
2024
Q2 		$288K Sell
2,093
-1
-0% -$137 ﹤0.01% 1341
2024
Q1 		$289K Buy
2,094
+34
+2% +$4.64K ﹤0.01% 1340
2023
Q4 		$271K Buy
2,060
+10
+0.5% +$1.15K ﹤0.01% 1315
2023
Q3 		$231K Buy
+2,050
New +$216K ﹤0.01% 1347

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrated Wealth Concepts's NBIX Position: Q2 2026 in Review

Integrated Wealth Concepts reduced its Neurocrine Biosciences (NBIX) stake by 41% in Q2 2026, selling an estimated $846K and leaving 8,041 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #1036.

Integrated Wealth Concepts first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.81M in Q1 2026. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Integrated Wealth Concepts held 8,041 shares of Neurocrine Biosciences worth $1.36M as of Q2 2026.
  • Integrated Wealth Concepts sold 5,703 Neurocrine Biosciences shares in Q2 2026, an estimated $846K.
  • Neurocrine Biosciences made up 0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #1036 holding.
  • Integrated Wealth Concepts first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Integrated Wealth Concepts's Neurocrine Biosciences position peaked at $1.81M in Q1 2026.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.